11 August 2020
Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to announce the publication of the first manuscript of the LuPIN trial in the journal, European Urology Oncology. This journal is the first official publication of the European Association of Urology that is fully devoted to the study of genitourinary cancer. The publication has been peer-reviewed by a panel of experts in the field.
The authors are renowned medical experts from the Kinghorn Cancer Centre, St Vincent’s Hospital Sydney, Garvan Institute of Medical Research, Monash University, Sir Peter MacCallum Dept of Oncology, and Princess Margaret Cancer Center, Toronto.
NOX has announced previously interim information about the LuPIN trial on 14th February 2020. The peer- reviewed publication released today describes the details of the LuPIN study, its background, design, treatment interventions and the outcomes for the first 32 patients in this 56-patient study.
The potential of Veyonda®
The authors concluded that in late-stage prostate cancer patients who have exhausted all standard treatment options, a combination of 177LuPSMA-617 and Veyonda® is both safe and delivered promising efficacy outcomes, among them a median Overall Survival of 17.1 months. The authors noted that the median Overall Survival in a study conducted in a comparable patient population (exhausted all standard treatment options; progressive disease) receiving standard chemotherapy was only 4.5 months.’
Noxopharm Executive Chairman and CEO Graham Kelly said: “This is excellent news for Noxopharm and adds to the growing evidence that Veyonda® has the means to become a standard of care drug in late-stage prostate cancer. Lu-PSMA-617 therapy is attracting considerable international attention as a promising therapy for men with Stage 4 prostate cancer. It was the subject of a US$6 billion series of acquisitions by Novartis in 2018 and we anticipate it becoming a commercially available drug in 2021.
